Impact of Linker Composition on VHL PROTAC Cell Permeability
Journal of Medicinal Chemistry · 09.01.2025 · 68 (1) · 638-657
DOI: 10.1021/acs.jmedchem.4c02492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 18.12.2024. Verfasst von Yordanos Esubalew Abeje und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry─BMC, Uppsala University, Box 576, 75123 Uppsala, Sweden. Hauptthemen laut MEDLINE: Von Hippel-Lindau Tumor Suppressor Protein, Cell Membrane Permeability, Proteolysis. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsr?det, Bayer.
Abstract (Originalsprache)
The discovery of cell permeable and orally bioavailable von Hippel-Lindau (VHL) proteolysis targeting chimeras (PROTACs) is challenging as their structures locates them at, or beyond, the outer limits of oral druggable space. We have designed a set of nine VHL PROTACs and found that the linker had a profound impact on passive cell permeability. Determination of the solution ensembles in a nonpolar solvent revealed that high permeability was correlated to the ability of the PROTACs to adopt folded conformations that have a low solvent accessible 3D polar surface area. Our results suggest that the design of cell permeable VHL PROTACs could focus on linkers that facilitate shielding of polar surface area in the VHL ligand in a nonpolar but not in a polar environment. In addition, we found that not only intramolecular hydrogen bonds, but also NH-π and π-π interactions contribute to the stabilization of low-polarity conformations, and thereby to high cell permeability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry─BMC, Uppsala University, Box 576, 75123 Uppsala, Sweden.
- Bayer AG, Drug Discovery Sciences, 42113 Wuppertal, Germany.
ORCID-Profile: Lianne H E Wieske, Vasanthanathan Poongavanam, Mate Erdelyi, Daniel Meibom, Jan Kihlberg
Förderung
- Vetenskapsr?det
- Bayer
Zitieren
APA
Abeje, Y. E., Wieske, L. H. E., Poongavanam, V., Maassen, S., Atilaw, Y., Cromm, P., Lehmann, L., Erdelyi, M., Meibom, D., & Kihlberg, J. (2025). Impact of Linker Composition on VHL PROTAC Cell Permeability. Journal of Medicinal Chemistry, 68(1), 638-657. https://doi.org/10.1021/acs.jmedchem.4c02492
Vancouver
Abeje YE, Wieske LHE, Poongavanam V, Maassen S, Atilaw Y, Cromm P, et al. Impact of Linker Composition on VHL PROTAC Cell Permeability. Journal of Medicinal Chemistry. 2025;68(1):638-657. doi:10.1021/acs.jmedchem.4c02492
BibTeX
@article{Abeje2025,
author = {Abeje, Yordanos Esubalew and Wieske, Lianne H E and Poongavanam, Vasanthanathan and Maassen, Stefanie and Atilaw, Yoseph and Cromm, Philipp and Lehmann, Lutz and Erdelyi, Mate and Meibom, Daniel and Kihlberg, Jan},
title = {Impact of Linker Composition on VHL PROTAC Cell Permeability},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {1},
pages = {638--657},
doi = {10.1021/acs.jmedchem.4c02492}
}
EUVIMED